Psyched Wellness and the National Research Council of Canada (NRC) have announced preliminary data from studies of the neuroprotective and anti-inflammatory properties of AME-1.
Preliminary findings from the Psyched Wellness and NRC studies demonstrate the anti-inflammatory properties of AME-1. They also indicate that AME-1 does not cause apoptosis while also having a neuroprotective effect at the cellular level.
Brian Tancowny, Scientific Advisor to Psyched Wellness commented: “The preliminary evidence of this investigative study revealed more key functional properties of the AME-1 extract and its broader health and wellness benefits.
“The neuroprotective effect found in this study is unique, and the potential impacts from a natural product such as AME-1 are novel. The amanita muscaria mushroom’s functional properties will be further explored, and will we continue to build our knowledge base on the amazing potential healing power of AME-1.”
The first part of the analysis focused on the ability of AME-1 to protect neuronal microglial cells from inflammatory mediator-induced apoptosis (the process whereby the cell undergoes a cell programmed cell death), and monitored the cell surface expression of apoptotic markers using annexin V and propidium iodide.
The results of the study showed at the cellular level that AME-1 did have a neuroprotective effect on microglial cells that were treated with a pro-inflammatory mediator, and this was determined to be concentration dependence.
The second part of the study was to determine whether AME-1 has any direct inhibitory effects on one of the pro-apoptotic cellular pathways, such as the induction of caspase-3. Caspase-3 has been published to be important in the apoptotic process and is responsible for proteolytic cleavage of key proteins in the cell nucleus.
AME-1 did not increase caspase-3 activity, and did not induce any apoptotic or cell death effects. However, there was no inhibition of this pathway which can be explained by the fact AME-1 may influence another apoptotic pathway not investigated yet.
Psyched Wellness CEO, Jeffrey Stevens, stated: “It is exciting to see continued positive results from the studies we are conducting with the NRC, and further work is being done to examine the mechanisms of this neuroprotection as we learn more about the amanita muscaria.
“As we focus on commercialisation of our AME-1 tinctures in the United States this Spring, these studies provide evidence for the potential of many additional future uses of AME-1 to ensure we can offer consumers options for their health and wellness needs.”
The NRC is an agency of the Government of Canada, and specialises in providing vital scientific and technological services to the research and industrial communities of Canada. The NRC was hired to provide their expertise in biomedical nanotechnology, but all the results of the research will belong to Psyched, and the NRC does not endorse the findings or Psyched products.
[activecampaign form=52]
